普洛药业：公司CDMO业务相较于原料药业务表现更加亮眼

Group 1 - The core viewpoint of the article is that the company's CDMO business is outperforming its API business, indicating a shift in growth dynamics [1] - The API business is currently at the bottom of the industry cycle, leading to year-on-year performance pressure [1] - The CDMO business is entering a harvest phase, which is expected to drive the company's performance into a new growth stage [1]